Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
The conversation is about someone's hair regrowth progress using Hims serum from February 25th to April 6th. Users commented on the noticeable improvement and potential for full hair recovery.
Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The conversation discusses using Spironolactone for hairline regrowth while continuing with dutasteride and oral Minoxidil. Concerns are raised about losing regrown hair after stopping Spironolactone.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.
User considers scalp micropigmentation (SMP) for hair loss. Mixed opinions shared; some regret it, others satisfied. Choosing reputable clinic and technician is important.
Topical spironolactone is discussed as a potential treatment for androgenic alopecia, with the user seeking feedback on its effectiveness. Minoxidil, finasteride, and other treatments like microneedling and keto shampoo are mentioned as alternatives.
The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.
A user noticed non-itchy, non-bleeding spots on their scalp while experiencing hair loss. Replies suggest the spots are likely sunspots or liver spots and recommend seeing a dermatologist; hair loss is attributed to male pattern baldness.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
Female experiencing hair loss for 10 years used 50mg Spironolactone and 5% minoxidil with decent results. Recently had massive shedding, but blood tests were fine and still taking original medications.
Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.
Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.
A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.